Filter By Category
Archives
Share on -
CUTAMESINE
Generic Name: CUTAMESINE
ABSTRACT -
Cutamesine, also known as SA4503, is a selective sigma-1 receptor agonist investigated for neuropsychiatric and neurologic indications. Clinical development has explored effects on functional recovery, cognition, mood, and neuroprotection, but routine approved therapeutic use is not established.
DOSAGE -
No approved standard dosing is established. Published clinical studies have evaluated oral doses such as 1 mg or 3 mg daily for limited study periods; dosing should follow only an approved protocol or product label.
SIDE EEFECTS -
- Headache, dizziness, somnolence, or insomnia
- Nausea, abdominal discomfort, dry mouth, or appetite change
- Fatigue, nervousness, or mild tremor
- Transient changes in blood pressure or heart rate
- Laboratory or ECG monitoring changes in study settings
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Skin rash, itching, or hives
- Swelling of the face, lips, tongue, or throat
- Wheezing, chest tightness, or difficulty breathing
- Severe dizziness or fainting
DRUG INTERACTIONS-
- Other central nervous system-active drugs may alter sedation, dizziness, or neuropsychiatric effects
- Alcohol may worsen dizziness or impaired coordination
- Strong metabolic inhibitors or inducers should be considered cautiously because interaction data are limited
- Concomitant investigational drugs require protocol-specific review
PREAUTONS–
- Use only in settings where investigational or approved use is permitted
- Use caution in patients with seizure disorders, psychiatric instability, or significant cardiac disease
- Avoid driving or hazardous tasks until individual response is known
- Pregnancy and lactation safety are not established
- Monitor tolerability, vital signs, and concomitant CNS medicines
WARNINGS –
- Investigational/development status varies by country and indication
- Do not use as a substitute for approved treatments for depression, stroke, ALS, or retinal disease
- Safety data are limited compared with established medicines
- Discontinue and seek medical advice if severe neurologic, psychiatric, or allergic symptoms occur
Share on -
. Developed by